Aduro Biotech, Inc. (ADRO) News
Filter ADRO News Items
ADRO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ADRO News From Around the Web
Below are the latest news stories about Aduro Biotech Inc that investors may wish to consider to help them evaluate ADRO as an investment opportunity.
Aduro Biotech, American Renal Associates leads healthcare gainers; Benitec Biopharma, Mesoblast among major losersGainers: Aduro Biotech (ADRO) +442%, American Renal Associates (ARA) +69%, Nano-X Imaging (NNOX) +38%, CTI BioPharma (CTIC) +18%, ProPhase Labs (PRPH) +16%.Losers: Benitec Biopharma (BNTC) -36%, Mesoblast (MESO) -36%, Arcutis Biotherapeutics (ARQT) -14%, PDL BioPharma (PDLI) -13%, Electromed (ELMD) -12%.... |
Healthcare - Top 5 Gainers / LosersGainers: Aduro Biotech (ADRO) +20%. Otonomy (OTIC) +14%. BeyondSpring (BYSI) +13%. Verrica Pharmaceuticals (VRCA) +13%. STRATA Skin Sciences (SSKN) +11%.Losers: Poseida Therapeutics (PSTX) -30%. Acer Therapeutics (ACER) -20%. Biofrontera (BFRA) -15%. Unity Biotechnology (UBX) -11%. Interpace Biosciences (IDXG) -10%.... |
Aduro Biotech Provides Business Update and Reports Second Quarter 2020 Financial ResultsBERKELEY, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing… |
Hedge Funds Are Warming Up To Aduro BioTech Inc (ADRO)Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […] |
Dosing underway in Aduro Bio's BION-1301 study for kidney diseaseAduro Biotech (ADRO) doses first patient with IgA nephropathy in a Phase 1 clinical trial of BION-1301, an investigational humanized IgG4 monoclonal antibody. Part 3 of the Phase 1 multi-center trial is evaluating the safety and tolerability of BION-1301 in two cohorts of 20 total adult subjects. Parts 1 and 2 of... |
Aduro Biotech Announces First Patient Dosed in Phase 1 Study of BION-1301 in IgA NephropathyAduro Biotech, Inc. (ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced that the first patient with IgA nephropathy has been dosed in a Phase 1 clinical trial of BION-1301, an investigational humanized IgG4 monoclonal antibody that blocks APRIL binding to both the BCMA and TACI receptors. “We are thrilled to have dosed the first patient with IgA nephropathy in the Phase 1 clinical study of our investigational anti-APRIL antibody, BION-1301,” said Dimitry S.A. Nuyten, M.D., Ph.D., chief medical officer of Aduro. |
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Aduro Biotech, Inc. (ADRO) and Encourages Investors to Contact the FirmPHILADELPHIA, PA / ACCESSWIRE / June 18, 2020 / Kaskela Law LLC announces that it is investigating Aduro Biotech, Inc. ("Aduro Biotech") (NASDAQ:ADRO) on behalf of the company's shareholders. ... |
Aduro Biotech and Chinook Therapeutics to mergeAduro Biotech (ADRO) has agreed to merge with privately held Chinook Therapeutics in an all-stock deal. Specifically, Aduro will acquire 100% of Chinook in exchange for 50% of its outstanding capital stock.The combined company will do business as Chinook Therapeutics and shares will trade on the Nasdaq Global Market under... |
Aduro Biotech Presents Nonclinical and Phase 1 Healthy Volunteer Data for BION-1301 at the 57th ERA-EDTA Virtual CongressAduro Biotech, Inc. (ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced the presentation of healthy volunteer data from the ongoing Phase 1 study of BION-1301 for the treatment of IgA nephropathy as well as data from long-term nonclinical studies. The findings are being presented as posters at the 57th European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Fully Virtual Congress. |
Aduro Biotech and Chinook Therapeutics Announce Definitive Merger Agreement– Combined Company Will Operate as Chinook Therapeutics and Advance Pipeline of Clinical-Stage Programs in Kidney Diseases, Led by Atrasentan and BION-1301 in IgA Nephropathy –. |